JP2024540320A5 - - Google Patents

Info

Publication number
JP2024540320A5
JP2024540320A5 JP2024526671A JP2024526671A JP2024540320A5 JP 2024540320 A5 JP2024540320 A5 JP 2024540320A5 JP 2024526671 A JP2024526671 A JP 2024526671A JP 2024526671 A JP2024526671 A JP 2024526671A JP 2024540320 A5 JP2024540320 A5 JP 2024540320A5
Authority
JP
Japan
Prior art keywords
cells
approximately
subject
dose
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079190 external-priority patent/WO2023081735A1/en
Publication of JP2024540320A publication Critical patent/JP2024540320A/ja
Publication of JP2024540320A5 publication Critical patent/JP2024540320A5/ja
Pending legal-status Critical Current

Links

JP2024526671A 2021-11-03 2022-11-02 骨髄腫を処置する際に使用するための、b細胞成熟抗原に特異的なキメラ抗原受容体 Pending JP2024540320A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275414P 2021-11-03 2021-11-03
US63/275,414 2021-11-03
US202163287904P 2021-12-09 2021-12-09
US63/287,904 2021-12-09
PCT/US2022/079190 WO2023081735A1 (en) 2021-11-03 2022-11-02 Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma

Publications (2)

Publication Number Publication Date
JP2024540320A JP2024540320A (ja) 2024-10-31
JP2024540320A5 true JP2024540320A5 (enExample) 2025-11-11

Family

ID=84537468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526671A Pending JP2024540320A (ja) 2021-11-03 2022-11-02 骨髄腫を処置する際に使用するための、b細胞成熟抗原に特異的なキメラ抗原受容体

Country Status (4)

Country Link
EP (1) EP4426339A1 (enExample)
JP (1) JP2024540320A (enExample)
KR (1) KR20240112994A (enExample)
WO (1) WO2023081735A1 (enExample)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
PL3198345T3 (pl) 2014-09-22 2021-08-23 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linia do produkcji pojedynczych wyrobów w następujących po sobie w cyklu ciągłym
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
HRP20191873T1 (hr) 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
WO2018028647A1 (en) 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
WO2018085690A1 (en) 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
CA3040533A1 (en) 2016-12-02 2018-06-07 Cartesian Therapeutics, Inc. Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
WO2018133877A1 (zh) 2017-01-23 2018-07-26 科济生物医药(上海)有限公司 靶向bcma的抗体及其应用
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
US11807663B2 (en) 2018-02-01 2023-11-07 Innovent Biologics (Suzhou) Co., Ltd. Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof
TWI908706B (zh) 2018-03-07 2025-12-21 美商波西達治療公司 CARTyrin組成物和使用方法
KR102718800B1 (ko) * 2018-05-23 2024-10-18 셀진 코포레이션 다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
TW202019474A (zh) * 2018-07-11 2020-06-01 美商西建公司 抗bcma嵌合抗原受體之用途
AU2019335014A1 (en) 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2020112796A1 (en) 2018-12-01 2020-06-04 Allogene Therapeutics, Inc. Chimeric antigen receptors targeting b-cell maturation antigen and methods of use thereof
WO2021091978A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
MX2022010340A (es) 2020-02-24 2022-09-19 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas.

Similar Documents

Publication Publication Date Title
US20250262318A1 (en) Methods and pharmaceutical composition for the treatment of cancer
AU2017302668B2 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
JP2022512917A5 (enExample)
JP7384835B2 (ja) Cd3に特異的な抗体及びその使用
JP2021501606A5 (enExample)
TW201625270A (zh) 用於治療贅瘤形成的治療組合及方法
US20260116971A1 (en) Antibodies specific to human nectin-2
JP2018521008A (ja) 腫瘍形成を処置するための治療用組成物および治療方法
EP3774903A1 (en) Anti-cd27 antibodies and uses thereof
JP2020519579A (ja) Lrrc33阻害剤およびその使用
JP2023522857A5 (enExample)
JP2021512107A5 (enExample)
JP2023524430A5 (enExample)
JP2025175307A (ja) 逐次抗cd19治療
EP3692066A2 (en) Combination treatment for cancer
JP2023513434A5 (enExample)
JP2024513054A5 (enExample)
JP2022554353A5 (enExample)
JP2024540320A5 (enExample)
JP2024514163A5 (enExample)
CN119013309A (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
EA048837B1 (ru) Ступенчатая анти-cd19 терапия
CN121487961A (zh) 抗kras/hla抗体及其用途